Australian Operations
Include All CSL Behring Country Sites

Australian Operations

CSL Behring, formerly a part of CSL Biotherapies, is Australia’s chosen national plasma fractionator and, under contract to Australia’s National Blood Authority, manufactures a complete range of life saving plasma-derived therapies for the treatment of the Australian community. 

The range of plasma-derived therapies we manufacture for Australia is the largest manufactured in a single facility globally. It is also the only range in which every product is manufactured using processes that include at least two dedicated and complementary pathogen reduction steps. We are also the chosen national plasma fractionator of New Zealand, Hong Kong, Malaysia, Singapore and Taiwan. 

In Australia, CSL Behring is a member of Medicines Australia (MA) and complies with the MA Code of Conduct. We have prepared the following reportable transfers of payment report for publication in accordance with Edition 18 of the MA Code of Conduct, and in a manner consistent with Australia’s Privacy legislation.

About CSL Behring

CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide. 

CSL Behring therapies are used around the world to treat coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease, and neurological disorders in certain markets. The company’s products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn.

Our products are produced at facilities in Bern, Switzerland; Marburg, Germany; Kankakee, Illinois and Broadmeadows, Australia, in accordance with international safety and quality standards. Additionally, CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company, which operates worldwide from its headquarters in Melbourne, Australia.

For more information about the company, please visit the global CSL Behring website.

CSL Delivering on Our Promise

100 years of CSL history – what we do and how we do it, with added perspective from our patients.

Our Values

The CSL Group Values set a foundation for working across the organisation and serve as a tool in decision-making in the diverse businesses that form the CSL Group.

Our Values bind the CSL group of companies together through a shared commitment to:

  • Patient Focus
    We deliver on our promise to patients
  • Innovation
    We turn innovative thinking into solutions
  • Integrity
    We walk the talk
  • Collaboration
    We are stronger together
  • Superior Performance
    We take pride in our results